Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Apr;19(4):194.
doi: 10.1038/s41585-022-00579-0.

Darolutamide combo is an ARASENSible option for mHSPC

Annette Fenner  1
Affiliations
Comment

Darolutamide combo is an ARASENSible option for mHSPC

Annette Fenner. Nat Rev Urol. 2022 Apr.
No abstract available

PubMed Disclaimer

Comment in

Comment on

  • Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Smith MR, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. N Engl J Med. 2022. PMID: 35179323 Free PMC article. Clinical Trial.

References

Original article
    1. Smith, M. R. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2119115 (2022) - DOI - PubMed - PMC
Related article
    1. Lokeshwar, S. D., Klaassen, Z. & Saad, F. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nat. Rev. Urol. 18, 433–442 (2021) - DOI

LinkOut - more resources